GT200500328A - Sal l-tartrato de n-1-adamantil-2-{3-[(2r)-2-({(2r)-2-hidroxi-2[4-hidroxi-3-(hidroximetil)fenil]etil}amino)propil]fenil}acetamida. - Google Patents

Sal l-tartrato de n-1-adamantil-2-{3-[(2r)-2-({(2r)-2-hidroxi-2[4-hidroxi-3-(hidroximetil)fenil]etil}amino)propil]fenil}acetamida.

Info

Publication number
GT200500328A
GT200500328A GT200500328A GT200500328A GT200500328A GT 200500328 A GT200500328 A GT 200500328A GT 200500328 A GT200500328 A GT 200500328A GT 200500328 A GT200500328 A GT 200500328A GT 200500328 A GT200500328 A GT 200500328A
Authority
GT
Guatemala
Prior art keywords
phenyl
hydroximethyl
propil
etil
acetamide
Prior art date
Application number
GT200500328A
Other languages
English (en)
Spanish (es)
Inventor
Kim James
Stefan Colin John Taylor
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of GT200500328A publication Critical patent/GT200500328A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GT200500328A 2004-11-12 2005-11-11 Sal l-tartrato de n-1-adamantil-2-{3-[(2r)-2-({(2r)-2-hidroxi-2[4-hidroxi-3-(hidroximetil)fenil]etil}amino)propil]fenil}acetamida. GT200500328A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0425057A GB0425057D0 (en) 2004-11-12 2004-11-12 L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide

Publications (1)

Publication Number Publication Date
GT200500328A true GT200500328A (es) 2006-06-02

Family

ID=33523659

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500328A GT200500328A (es) 2004-11-12 2005-11-11 Sal l-tartrato de n-1-adamantil-2-{3-[(2r)-2-({(2r)-2-hidroxi-2[4-hidroxi-3-(hidroximetil)fenil]etil}amino)propil]fenil}acetamida.

Country Status (8)

Country Link
AR (1) AR055282A1 (zh)
GB (1) GB0425057D0 (zh)
GT (1) GT200500328A (zh)
NL (1) NL1030405C2 (zh)
PE (1) PE20061131A1 (zh)
TW (1) TW200630324A (zh)
UY (1) UY29207A1 (zh)
WO (1) WO2006051375A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60318193T2 (de) * 2002-04-25 2008-12-04 Glaxo Group Ltd., Greenford Phenethanolaminderivate
EP1460064A1 (en) * 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
EP1577291A1 (en) * 2004-03-17 2005-09-21 Pfizer Limited Phenylethanolamine derivatives as beta-2 agonists

Also Published As

Publication number Publication date
PE20061131A1 (es) 2006-10-20
WO2006051375A1 (en) 2006-05-18
UY29207A1 (es) 2006-06-30
GB0425057D0 (en) 2004-12-15
TW200630324A (en) 2006-09-01
NL1030405A1 (nl) 2006-05-15
NL1030405C2 (nl) 2006-12-12
AR055282A1 (es) 2007-08-15

Similar Documents

Publication Publication Date Title
GT200500328A (es) Sal l-tartrato de n-1-adamantil-2-{3-[(2r)-2-({(2r)-2-hidroxi-2[4-hidroxi-3-(hidroximetil)fenil]etil}amino)propil]fenil}acetamida.
GT201100127A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
RU2010129238A (ru) Применение производных изотиоцианата в качестве противомиеломных средств
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
GT200500378A (es) Macrolidos
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
AR060880A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
CL2007001917A1 (es) Compuestos derivados de azaindol espirociclicos; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del dolor, condiciones de panico, depresion, mal de alzheimer, migrana, entre otras.
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
DK1932522T3 (da) Terapeutisk middel mod leversygdom indeholdende 2-amino-1,3-propandiolderivat som aktiv bestanddel
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
CL2008001297A1 (es) N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer.
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
CL2007003289A1 (es) Compuestos derivados de biciclocarboxiamida; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades provocadas por la hiperactivacion del receptor vc1 como dolor, enfermedad de vejiga, inflam
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
UY31346A1 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo